Business

Sales of Celgene’s marquee cancer drug surge as Trump’s price-crackdown looms

By Joe Williams
Published May 4, 2018 2:11pm ET
Add Washington Examiner on Google
Sales of Celgene’s marquee cancer drug surge as Trump’s price-crackdown looms
President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

Sales of Celgene’s marquee cancer drug are growing despite questions about how the Trump administration’s plan to address rising drug costs will affect pharmacy companies.

[Trump speech on drug prices set for May 11, sources say]

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Antitrust Donald Trump FDA Pharmaceutical Industry